Key result
HCM requires systematic clinical and genetic profiling to guide pharmacotherapy and stratify SCD risk.
The paper highlights the ongoing need for systematic approaches to identify clinical, genetic, and environmental markers to guide pharmacotherapy and assess sudden cardiac death risk in hypertrophic cardiomyopathy.
Emphasizes systematic marker identification in HCM; leaves open prospective validation for pharmacotherapy and SCD risk stratification.
The problem of studying hypertrophic cardiomyopathy (HCM) continues to maintain its relevance, given the prevalence of the disease (1:500), and the risk of sudden cardiac death (SCD) in people of young working age. A matter of great interest are the issues of finding additional clinical, instrumental and genetic markers, environmental factors that can influence the formation of clinical variants of the course of hypertrophic cardiomyopathy, the risk of SCD and prognosis in HCM. We need a systematic approach to the formation of different forms and variants with HCM to develop tactics of treatment of patients and the formulation of risk factors for SCD.
No takes yet. Share an insight, caveat, or question.
Kaplunova et al. (2018) studied this question. Hypertrophic cardiomyopathy (prevalence 1:500) requires a systematic approach to identifying clinical and genetic markers to guide pharmacotherapy and stratify sudden cardiac death risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: